Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease
Fig 6
In vitro and in vivo effects of eculizumab in PNH disease.
(A) Observed (symbols) and simulated (line, module 1–3) inhibition of PNH erythrocyte lysis in vitro as a function of eculizumab concentration. (B) Observed (symbols) and simulated (line, module 1–5) recovery of hemoglobin levels in PNH patients treated for 36 months with eculizumab. The experimental data was digitized from [77] (A) and [74] (B).